Serynth Wart Removal System

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry fully. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, use is contraindicated in patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only; it is imperative to keep the product away from fire and flame to prevent any potential hazards.

General precautions must be observed to ensure safe application. The product should not be used on irritated skin or any area that is infected or reddened. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought. Contact a Poison Control Center at 1-800-222-1222 without delay.

Users are advised to discontinue use and consult a healthcare professional if discomfort persists, ensuring that any ongoing issues are appropriately addressed.

Side Effects

Patients should be aware that the product is for external use only and should be kept away from fire and flame to prevent any potential hazards.

In clinical practice, if discomfort persists after application, patients are advised to stop use and consult a healthcare professional. This recommendation is crucial to ensure safety and address any underlying issues that may arise from continued use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Serynth Wart Removal System (salicylic acid 17% wart removal system). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

The product has not been evaluated for safety in pregnancy. Caution is advised as the safety of salicylic acid during pregnancy is not established. While specific potential risks associated with the use of salicylic acid during pregnancy are not detailed, healthcare providers should be consulted before use, particularly for pregnant patients or those planning to become pregnant. No specific dosage modifications for pregnant individuals are provided. Given the lack of established safety data, healthcare professionals should carefully consider the risks and benefits when prescribing this product to women of childbearing potential.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, no data are provided concerning the excretion of the drug in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or a medical toxicologist may also be beneficial in managing the case effectively.

It is crucial to document all findings and interventions in the patient's medical record to ensure continuity of care and facilitate further management.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to emphasize the necessity of prompt action in such situations.

Patients should be informed to avoid contact with their eyes. In the event that the product does come into contact with the eyes, they should flush the eyes with water for at least 15 minutes and seek medical attention if irritation persists.

Additionally, healthcare providers should instruct patients that the product is non-edible and should be stored securely. Patients should be reminded to cap the product tightly and keep it at room temperature, away from heat sources, to ensure safety and efficacy.

Finally, patients should be counseled to discontinue use of the product and consult a healthcare professional if they experience any discomfort that persists. This guidance is crucial for ensuring patient safety and effective use of the product.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes. Additionally, if the product is ingested, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

Drug Information (PDF)

This file contains official product information for Serynth Wart Removal System, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)